Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NSD2 | O96028 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 12/20 | 0.36 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31600450 | 0.98 | KDM4E (0.51) | KDM4EMAPTNSD2ALDH1A1MAOA | |
| SCHEMBL13980264 | 0.79 | MAPT (0.46) | KDM4EMAPTNSD2ALDH1A1MAOA | |
| SCHEMBL30665076 | 0.79 | ALDH1A1 (0.55) | KDM4EMAPTNSD2ALDH1A1BRD4 | |
| SCHEMBL21631704 | 0.78 | MAPT (0.44) | KDM4EMAPTNSD2ALDH1A1MAOA | |
| SCHEMBL25104925 | 0.78 | ALDH1A1 (0.53) | KDM4EMAPTNSD2ALDH1A1MAOA | |
| SCHEMBL29109564 | 0.78 | MAPT (0.53) | KDM4EMAPTNSD2ALDH1A1MAOA | |
| SCHEMBL21246780 | 0.78 | KDM4E (0.53) | KDM4EMAPTNSD2ALDH1A1MAOA | |
| Hydrochloric Acid SCHEMBL31600876 | 0.78 | ALDH1A1 (0.53) | KDM4EMAPTNSD2ALDH1A1BRD4 | |
| SCHEMBL22095608 | 0.77 | KDM4E (0.45) | KDM4EMAPTNSD2ALDH1A1MAOA | |
| SCHEMBL31600799 | 0.77 | KDM4E (0.49) | KDM4EMAPTNSD2ALDH1A1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055363-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4724438-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025085233-A1 | NOVEL DERIVATIVES OF QUINOLINONES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2024259015-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-3164509-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-106604997-B | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2021-02-19 | — | — | CN | disclosed |
| US-10626104-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10626103-B2 | Inhibitor of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10626103-B2 | Inhibitor of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10626104-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10414750-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414750-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190194161-A1 | INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194162-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194162-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194161-A1 | INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20180265491-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-09-20 | — | — | US | disclosed |
| EP-3164509-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016004105-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626104-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | KDM4E 16/4885MAPT 3093/4885NSD2 149/4885 |
| US-10414750-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | KDM4E 16/4885MAPT 3093/4885NSD2 149/4885 |
| US-10626103-B2 | Inhibitor of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | KDM4E 15/4885MAPT 2977/4885NSD2 150/4885 |
| US-20190194161-A1 | INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM4E 15/4885MAPT 2977/4885NSD2 150/4885 |
| US-20190194162-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM4E 16/4885MAPT 3093/4885NSD2 149/4885 |
| US-20180265491-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM4E 16/4885MAPT 3093/4885NSD2 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.